| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG |
|
| Chemical and physical data | |
| Formula | C23H28O6 |
| Molar mass | 400.471 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Enprostil is a syntheticprostaglandin designed to resembledinoprostone. Enprostil was found to be a highly potent inhibitor of gastric HCl secretion.[1] It is an analog ofprostaglandin E2 but unlike this prostaglandin, which binds to and activates all four cellularreceptors viz.,EP1,EP2,EP3, andEP4 receptors, enprostil is a more selectivereceptor agonist in that it binds to and activates primarily the EP3 receptor.[2] Consequently, enprostil is expected to have a narrower range of actions that may avoid some of the unwanted side-effects and toxicities of prostaglandin E2. A prospective multicenter randomized controlled trial conducted in Japan found combining enprostil with cimetidine was more effective than cimetidine alone in treating gastric ulcer.[3]
Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |